Paper Details

  1. Home
  2. Paper Details

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

Author: BartonP, ChenY-F, ConnockM, Fry-SmithA, JobanputraP, LiuZ, MalottkiK, MooreD, RouthK, TsourapasA, UthmanA O

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

RTX and ABT are more effective than supportive care in patients with RA who have tried conventional agents and have failed to improve after trying a first tumour necrosis factor (TNF) inhibitor. At 6 months significantly more patients treated with RTX achieved ACR 20 [relative risk (RR) = 2.85, 95% confidence interval (CI) 2.08 to 3.91] and ACR70 (RR = 12.14, 95% CI 2.96 to 49.86) compared with those treated with the placebo.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Rheumatoid arthritis (RA) is an inflammatory condition that typically causes a symmetrical chronic arthritis. Timely use of disease-modifying antirheumatic drugs (DMARDs) is an essential aspect of disease management, but many patients may not respond even when conventional agents are use...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781257/

データ提供：米国国立医学図書館（NLM）

Rheumatoid Arthritis: Exploring New Frontiers in Treatment

Rheumatoid arthritis (RA), a chronic inflammatory disease, can significantly impact quality of life. This systematic review and economic evaluation assess the effectiveness and cost-effectiveness of various biologic therapies, including adalimumab, etanercept, infliximab, rituximab, and abatacept, for treating RA in patients who have not responded well to conventional medications. This research, like a meticulous desert cartographer mapping the intricate pathways of treatment options, aims to provide a comprehensive understanding of these advanced therapies.

Biologics: A New Oasis in the Desert of RA

The review finds that rituximab and abatacept demonstrate significant effectiveness in improving RA symptoms and achieving remission in patients who have not responded to conventional therapies. This discovery, like finding a fertile oasis in a barren desert, offers a glimmer of hope for those struggling with this challenging condition. However, the review also highlights the need for more head-to-head trials to compare the effectiveness and cost-effectiveness of these various biologics.

Navigating the Landscape of RA Treatment

This research underscores the importance of personalized medicine and careful consideration of treatment options for patients with RA. It reminds us that just as a desert traveler must choose the right path for their journey, clinicians must select the most appropriate treatment strategy for each individual patient, taking into account their specific needs and preferences.

Dr.Camel's Conclusion

This review provides a comprehensive overview of the evolving landscape of RA treatment, highlighting the potential benefits of biologics for patients who have not responded to conventional therapies. It's like a guidebook for navigating the complex terrain of RA, offering valuable insights into the latest advancements in treatment options. While more research is needed to fully understand the long-term impact of these biologics, this research offers a promising path towards improved outcomes for those living with this challenging condition.

Date :
  1. Date Completed 2011-08-05
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

21439251

DOI: Digital Object Identifier

PMC4781257

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.